(Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-2) of higher dose 9 mg mazdutide (Innovent R&D Code: IBI362) , a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity
Our GLP-1 agonist therapies, Semaglutide and Tirzepatide for weight loss, offer a proven path to lasting weight loss
About 65 percent of people on the highest dose reached a body mass index under 30, meaning they no longer met the clinical definition of obesity by the end of the study
A The mean weight loss was much greater in the oral semaglutide group compared with the placebo group
Medications such as Ozempic, Wegovy, and Mounjaro have brought GLP-1 into the spotlight by mimicking this natural hormone to improve metabolic control
Ultimately, whether microdosing becomes mainstream will depend on future clinical evidence